Lymphomas | Clinical

FDA Approves Crizotinib in Pediatric ALK+ Relapsed or Refractory Systemic ALCL

January 14, 2021

The FDA granted approval to the antineoplastic tyrosine kinase inhibitor, crizotinib, as treatment of pediatric patients 1 year of age and older and young adults with ALK alteration-positive relapsed or refractory systemic anaplastic large cell lymphoma.

Novel JAK1 Inhibitor Safely Induces Preliminary Antitumor Activity in R/R PTCL

January 06, 2021

The investigational selective JAK1 inhibitor, DZD4205, led to anti-tumor activity when given as treatment of patients with relapsed or refractory peripheral T-cell lymphoma , according to results from the phase 1/2 JACKPOT8 clinical trial.

Treating Double-Hit Lymphoma With CAR T-Cell Therapy and Other Drugs

January 04, 2021

During a Targeted Oncology Case-Based Peer Perspectives event, Haifaa Abdulhaq, MD, director, Hematology, and associate clinical professor of Medicine at UCSF Fresno discussed the case of a 63-year-old patient with lymphoma with concurrent MYC and BCL2 rearrangements.

Azacitadine Demonstrates Efficacy in a Phase 2 Trial of PTCL

December 18, 2020

Jia Ruan, MD, PhD, discusses the results of the multicenter phase 2 trial of oral azacitidine plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in patients with peripheral T-cell lymphoma.

Brentuximab Vedotin Tolerable With High Response Rates in Older Patients with cHL

December 08, 2020

In older patients with comorbid classical Hodgkin lymphoma who are deemed unfit for combination chemotherapy, treatment with the antibody dug conjugate brentuximab vedotin appeared tolerable and achieved high response rates that were durable in some patients, according to results from the phase 2 SGN35-015 study.